Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on cancer diagnosis: can a computer match expert pathologists?

NCT ID NCT07307157

Diagnosis Sponsor: Harvard Medical School (HMS and HSDM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can help improve cancer diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
COSMO AI system (digital pathology software)
What this could lead to
If successful, this could show that AI can help pathologists diagnose cancer subtypes more accurately and consistently, potentially speeding up diagnoses.
What could go wrong
This is a small, early-stage study with only 30 pathologists and 300 cases. The AI may not perform as well in real-world settings or on different types of cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We will recruit pathologists from international academic medical centers, hospital systems, and diagnostic pathology practices across North America (United States), Europe (Austria, Hungary), and the Asia-Pacific (Taiwan, Hong Kong, South Korea, China, India) region. Participating sites will include major academic institutions with established pathology departments, with recruitment targeting expertise in neuropathology, pulmonary pathology, and urologic pathology.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified pathologist with expertise in neuropathology, pulmonary pathology, urologic pathology, or general anatomical pathology * Minimum of 3 years of clinical diagnostic experience * Active clinical practice involving diagnostic pathology slide review * Willingness to independently review and diagnose up to 300 de-identified whole-slide images * Ability to access the study platform and complete case reviews within the specified study timeline * Provision of informed consent for study participation Exclusion Criteria: * Prior involvement in the design or validation of the COSMO AI system * Inability to commit sufficient time to complete assigned case reviews * Presence of significant financial conflicts of interest related to the study outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer disease kidney cancer lung cancer lung neoplasm renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain cancer Lung cancer (diagnosis) Renal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Harvard Medical School

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.